Rationale and design of the CORDIAL first-in-human clinical trial: A system for sorbent-assisted continuous flow peritoneal dialysis.

IF 3.7 3区 医学 Q2 UROLOGY & NEPHROLOGY
Joost Christiaan de Vries, Maaike K van Gelder, Dian P Bolhuis, Frank Simonis, Marianne C Verhaar, María Auxiliadora Bajo Rubio, Gloria Del Peso, Rafael Selgas, Gabriele Donati, Giulia Ligabue, Gianni Cappelli, Karin Gf Gerritsen
{"title":"Rationale and design of the CORDIAL first-in-human clinical trial: A system for sorbent-assisted continuous flow peritoneal dialysis.","authors":"Joost Christiaan de Vries, Maaike K van Gelder, Dian P Bolhuis, Frank Simonis, Marianne C Verhaar, María Auxiliadora Bajo Rubio, Gloria Del Peso, Rafael Selgas, Gabriele Donati, Giulia Ligabue, Gianni Cappelli, Karin Gf Gerritsen","doi":"10.1177/08968608251381933","DOIUrl":null,"url":null,"abstract":"<p><p>Peritoneal dialysis (PD) has important disadvantages compared to hemodialysis, including low plasma clearance and limited technique survival. A new device for sorbent-assisted (continuous flow) peritoneal dialysis (SAPD) has been designed that is based on continuous recirculation of peritoneal dialysate <i>via</i> a single-lumen peritoneal catheter with regeneration of spent dialysate by sorbents. SAPD treatment may enhance plasma clearance of uremic solutes by increasing the mass transfer area coefficient and maintenance of a high plasma-to-dialysate concentration gradient. In addition, SAPD treatment may preserve integrity of the peritoneal membrane for a longer period of time by avoiding the need for high initial glucose concentrations and by reducing the number of exchanges and (dis)connections of the peritoneal catheter, which may lower the risk of peritonitis. The primary aim of this first-in-human clinical trial is to evaluate the (short-term) clinical safety and performance of SAPD treatment in a small group (<i>n</i> = 12) of stable adult PD patients in a clinical setting (proof of concept). Key secondary objectives include an evaluation of efficacy in terms of plasma clearance, ultrafiltration, and patient tolerance.</p>","PeriodicalId":19969,"journal":{"name":"Peritoneal Dialysis International","volume":" ","pages":"8968608251381933"},"PeriodicalIF":3.7000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Peritoneal Dialysis International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/08968608251381933","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Peritoneal dialysis (PD) has important disadvantages compared to hemodialysis, including low plasma clearance and limited technique survival. A new device for sorbent-assisted (continuous flow) peritoneal dialysis (SAPD) has been designed that is based on continuous recirculation of peritoneal dialysate via a single-lumen peritoneal catheter with regeneration of spent dialysate by sorbents. SAPD treatment may enhance plasma clearance of uremic solutes by increasing the mass transfer area coefficient and maintenance of a high plasma-to-dialysate concentration gradient. In addition, SAPD treatment may preserve integrity of the peritoneal membrane for a longer period of time by avoiding the need for high initial glucose concentrations and by reducing the number of exchanges and (dis)connections of the peritoneal catheter, which may lower the risk of peritonitis. The primary aim of this first-in-human clinical trial is to evaluate the (short-term) clinical safety and performance of SAPD treatment in a small group (n = 12) of stable adult PD patients in a clinical setting (proof of concept). Key secondary objectives include an evaluation of efficacy in terms of plasma clearance, ultrafiltration, and patient tolerance.

首次人体临床试验的原理和设计:吸收剂辅助连续流腹膜透析系统。
与血液透析相比,腹膜透析(PD)有重要的缺点,包括低血浆清除率和有限的技术生存。一种新型的吸附剂辅助(连续流)腹膜透析(SAPD)装置已经被设计出来,它是基于通过单腔腹膜导管对腹膜透析液进行连续再循环,并用吸附剂再生用过的透析液。SAPD治疗可以通过增加传质面积系数和维持较高的血浆-透析液浓度梯度来增强血浆对尿毒症溶质的清除。此外,SAPD治疗可以避免需要高初始葡萄糖浓度,通过减少腹膜导管的交换和(断开)连接的次数,从而降低腹膜炎的风险,从而在更长的时间内保持腹膜的完整性。这项首次人体临床试验的主要目的是在临床环境中评估一小组(n = 12)稳定的成年PD患者SAPD治疗的(短期)临床安全性和性能(概念验证)。关键的次要目标包括评估血浆清除率、超滤和患者耐受性方面的疗效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Peritoneal Dialysis International
Peritoneal Dialysis International 医学-泌尿学与肾脏学
CiteScore
6.00
自引率
17.90%
发文量
69
审稿时长
6-12 weeks
期刊介绍: Peritoneal Dialysis International (PDI) is an international publication dedicated to peritoneal dialysis. PDI welcomes original contributions dealing with all aspects of peritoneal dialysis from scientists working in the peritoneal dialysis field around the world. Peritoneal Dialysis International is included in Index Medicus and indexed in Current Contents/Clinical Practice, the Science Citation Index, and Excerpta Medica (Nephrology/Urology Core Journal). It is also abstracted and indexed in Chemical Abstracts (CA), as well as being indexed in Embase as a priority journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信